Prior work
By Mike Rea
Positioning is not what you do to a mind. It is what you do to a product, before there is one. The argument behind POSITION: why the gap between strong science and a weak position opens in phase I and II, long before anyone writes a positioning statement.
is the same in phase I as on the day it launches. Everything else is a decision.
Every one of those is a positioning decision, whether the people making it call it that or not.
What it argued
The spine of the book: a manifesto for anyone who would rather decide what a medicine becomes than write a story about it later.
Indication, dose, formulation, endpoints and the value proposition are decided early in development. Differentiation is baked into the product from the outset, not bolted on by marketers afterwards.
Every phase that passes without an active positioning decision is a phase in which a passive one is made for you: by precedent, by convenience, by the standard of care.
Static positioning statements are graveyards for ambition. The future-tense version is a directive: it tells the development programme what to build, and the label is the proof that it worked.
The question is not "what does the drug do?" but "what is the point of your drug, to a customer?" It drives differentiation, communication, pricing and reimbursement.
Indication selection, comparators, brand naming and publication plans all position a drug by accident. If a decision will change what the product is, the person making it should know they are positioning it.
The book's opening experiment: one compound, handed to two firewalled teams at the end of pre-clinical.
A successful drug, on paper. And indistinguishable from the next three.
Same molecule. Different evidence, different label, different fight.
Both teams launched the same molecule. Only one of them launched a product anyone will remember.
How it relates to POSITION
Deep Positioning decides what the product is. POSITION decides what the market will be when the product arrives. The two are sequential, but interdependent.
A brilliantly positioned drug that enters a market not ready for it will underperform. A market shaped for a drug that was not positioned for it will not buy.
Get the book
How Molecules Become Great Medicines, by Mike Rea. For the people deciding, in phase I and II, what a medicine will become.